Liafensine

Source: Wikipedia, the free encyclopedia.
Liafensine
Clinical data
Routes of
administration		Oral
ATC code
  • None
Legal status
Legal status
  • Development terminated
Identifiers
  • 6-[(4S)-2-Methyl-4-(2-naphthyl)-1,2,3,4-tetrahydro-7-isoquinolinyl]-3-pyridazinamine
JSmol)
  • CN1C[C@H](C2=C(C1)C=C(C=C2)C3=NN=C(C=C3)N)C4=CC5=CC=CC=C5C=C4
  • InChI=1S/C24H22N4/c1-28-14-20-13-19(23-10-11-24(25)27-26-23)8-9-21(20)22(15-28)18-7-6-16-4-2-3-5-17(16)12-18/h2-13,22H,14-15H2,1H3,(H2,25,27)/t22-/m0/s1
  • Key:VCIBGDSRPUOBOG-QFIPXVFZSA-N

Liafensine (BMS-820836) is a

potential for abuse.[1] Another clinical trial of liafensine began in 2022.[3]

See also

References

  1. ^
    S2CID 222168896
    .
  2. ISBN 978-3-527-33384-4
    .
  3. ^ "CTG Labs - NCBI". clinicaltrials.gov. Retrieved 3 December 2023.


drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Liafensine&oldid=1188385373"